JP2016527215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527215A5 JP2016527215A5 JP2016524705A JP2016524705A JP2016527215A5 JP 2016527215 A5 JP2016527215 A5 JP 2016527215A5 JP 2016524705 A JP2016524705 A JP 2016524705A JP 2016524705 A JP2016524705 A JP 2016524705A JP 2016527215 A5 JP2016527215 A5 JP 2016527215A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- formula
- optionally substituted
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 38
- 229910052757 nitrogen Chemical group 0.000 claims 24
- 229910052717 sulfur Inorganic materials 0.000 claims 23
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 22
- 229910052760 oxygen Inorganic materials 0.000 claims 22
- 239000001301 oxygen Substances 0.000 claims 22
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 20
- 239000011593 sulfur Chemical group 0.000 claims 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 18
- 125000006413 ring segment Chemical group 0.000 claims 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000005549 heteroarylene group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000005651 substituted 1,4-phenylene group Chemical group 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 7
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000004474 heteroalkylene group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000005650 substituted phenylene group Chemical group 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000001851 biosynthetic effect Effects 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000031513 cyst Diseases 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 0 COC(C(C(Nc(cc1)ccc1C(*)=O)=O)NC(c(cc1)ccc1NC(c(cc1)ccc1[N+]([O-])=O)=O)=O)C([Rn])=O Chemical compound COC(C(C(Nc(cc1)ccc1C(*)=O)=O)NC(c(cc1)ccc1NC(c(cc1)ccc1[N+]([O-])=O)=O)=O)C([Rn])=O 0.000 description 2
- WMLWGVVLDSEQNF-UHFFFAOYSA-N CC(C)Oc(c(NC(c(cc1)ccc1NC(C(C(C(N)=O)OC)NC(c(cc1)ccc1NC(c(cc1)ccc1[N+]([O-])=O)=O)=O)=O)=O)ccc1C(Nc(c(OC)c2)ccc2C(O)=O)=O)c1O Chemical compound CC(C)Oc(c(NC(c(cc1)ccc1NC(C(C(C(N)=O)OC)NC(c(cc1)ccc1NC(c(cc1)ccc1[N+]([O-])=O)=O)=O)=O)=O)ccc1C(Nc(c(OC)c2)ccc2C(O)=O)=O)c1O WMLWGVVLDSEQNF-UHFFFAOYSA-N 0.000 description 1
- NGSYXDCEERWVTK-UHFFFAOYSA-N CC(C)Oc(c(NC(c(cc1)ccc1NC(C(C(C(N)=O)OC)NC(c(cc1)ccc1NC(c(cc1)ccc1[N+]([O-])=O)=O)=O)=O)=O)ccc1C(Nc(cc2)ccc2C(O)=O)=O)c1O Chemical compound CC(C)Oc(c(NC(c(cc1)ccc1NC(C(C(C(N)=O)OC)NC(c(cc1)ccc1NC(c(cc1)ccc1[N+]([O-])=O)=O)=O)=O)=O)ccc1C(Nc(cc2)ccc2C(O)=O)=O)c1O NGSYXDCEERWVTK-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003539 | 2013-07-12 | ||
| EP13003539.7 | 2013-07-12 | ||
| PCT/EP2014/001925 WO2015003816A2 (en) | 2013-07-12 | 2014-07-14 | Cystobactamides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527215A JP2016527215A (ja) | 2016-09-08 |
| JP2016527215A5 true JP2016527215A5 (OSRAM) | 2017-08-03 |
| JP6730183B2 JP6730183B2 (ja) | 2020-07-29 |
Family
ID=48792948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524705A Active JP6730183B2 (ja) | 2013-07-12 | 2014-07-14 | シストバクトアミド（Ｃｙｓｔｏｂａｃｔａｍｉｄｅｓ） |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20160145304A1 (OSRAM) |
| EP (1) | EP3019615B1 (OSRAM) |
| JP (1) | JP6730183B2 (OSRAM) |
| CN (1) | CN105793424B (OSRAM) |
| AU (1) | AU2014289663B2 (OSRAM) |
| CA (1) | CA2917767C (OSRAM) |
| WO (1) | WO2015003816A2 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3019615B1 (en) | 2013-07-12 | 2021-04-07 | Helmholtz-Zentrum für Infektionsforschung GmbH | Cystobactamides |
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| KR101747702B1 (ko) | 2014-05-15 | 2017-06-19 | 한국생명공학연구원 | 신규한 항균성 화합물 및 이의 용도 |
| WO2016082934A1 (en) * | 2014-11-26 | 2016-06-02 | Helmholtz-Zentrum für Infektionsforschung GmbH | Novel cystobactamides |
| CN105712894A (zh) * | 2016-03-23 | 2016-06-29 | 叶芳 | 一种3-甲氧基-4-氨基苯甲酸及其制备方法 |
| TWI725236B (zh) * | 2016-09-28 | 2021-04-21 | 日產化學工業股份有限公司 | 二胺及其之利用 |
| CN111065383A (zh) | 2017-07-11 | 2020-04-24 | 沃泰克斯药物股份有限公司 | 用作钠通道调节剂的羧酰胺 |
| CA3070240A1 (en) * | 2017-07-18 | 2019-01-24 | Technische Universitat Berlin | Novel albicidin derivatives, their use and synthesis |
| AU2018321152B2 (en) * | 2017-08-23 | 2023-07-06 | Helmholtz-Zentrum für Infektionsforschung GmbH | Novel cystobactamide derivatives |
| KR102717600B1 (ko) | 2017-10-06 | 2024-10-15 | 포르마 세라퓨틱스 인크. | 유비퀴틴 특이적 펩티다제 30의 억제 |
| WO2019139902A1 (en) | 2018-01-10 | 2019-07-18 | Zeno Royalties & Milestones, LLC | Benzamide compounds |
| MY196582A (en) | 2018-02-13 | 2023-04-19 | Gilead Sciences Inc | PD-1/PD-L1 Inhibitors |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN112513036B (zh) | 2018-05-17 | 2024-05-24 | 福马治疗有限公司 | 用作泛素特异性肽酶30抑制剂的稠合双环化合物 |
| PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
| ES2945834T3 (es) | 2018-10-05 | 2023-07-07 | Forma Therapeutics Inc | Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30) |
| EP3870566A1 (en) | 2018-10-24 | 2021-09-01 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US12440481B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| EP3994132A1 (en) | 2019-07-03 | 2022-05-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
| LT4069691T (lt) | 2019-12-06 | 2024-12-10 | Vertex Pharmaceuticals Incorporated | Pakeistieji tetrahidrofuranai kaip natrio kanalų moduliatoriai |
| CN117222438A (zh) * | 2021-03-31 | 2023-12-12 | 麦迪贝肯有限公司 | 取代的二氨基吡嗪二甲酸的纯化 |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| CN113563220B (zh) * | 2021-06-25 | 2023-08-29 | 华中农业大学 | 一种抗菌化合物及其应用 |
| WO2025003147A1 (en) | 2023-06-26 | 2025-01-02 | Helmholtz-Zentrum für Infektionsforschung GmbH | Cystobactamid derivatives |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4525354A (en) * | 1983-09-14 | 1985-06-25 | University Of Hawaii | Antibiotic and process for the production thereof |
| US7020622B1 (en) * | 1997-06-10 | 2006-03-28 | Linkshare Corporation | Transaction tracking, managing, assessment, and auditing data processing system and network |
| FR2772025B1 (fr) | 1997-12-10 | 2000-03-03 | Guerbet Sa | Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique |
| MXPA02010565A (es) * | 2000-04-28 | 2004-05-17 | Kosan Biosciences Inc | Produccion de policetidos. |
| KR20080015888A (ko) | 2000-06-28 | 2008-02-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 카르베딜올 |
| AU2003286498A1 (en) * | 2002-10-18 | 2004-05-04 | Centre De Cooperation Internationale En Recherche Agronomique Pour Le Developpement (Cirad) | Complete biosynthetic gene set for biosynthesis of albicidin, resistance genes, and uses thereof |
| US7803822B2 (en) | 2005-04-06 | 2010-09-28 | Takeda Pharmaceutical Company Limited | Triazole derivative and use thereof |
| JP5379965B2 (ja) * | 2006-09-26 | 2013-12-25 | 株式会社半導体エネルギー研究所 | スチルベン誘導体、発光素子および発光装置 |
| US7758972B2 (en) * | 2006-09-26 | 2010-07-20 | Semiconductor Energy Laboratory Co., Ltd. | Stilbene derivative, light emitting element, light emitting device, and electronic appliance |
| US7816324B2 (en) * | 2007-03-13 | 2010-10-19 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by a peptide receptor |
| US8236983B2 (en) * | 2008-03-13 | 2012-08-07 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by apoptosis |
| WO2013078277A1 (en) * | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
| WO2014125075A1 (en) * | 2013-02-15 | 2014-08-21 | Technische Universität Berlin | Albicidin derivatives, their use and synthesis |
| EP3019615B1 (en) * | 2013-07-12 | 2021-04-07 | Helmholtz-Zentrum für Infektionsforschung GmbH | Cystobactamides |
| KR101747702B1 (ko) | 2014-05-15 | 2017-06-19 | 한국생명공학연구원 | 신규한 항균성 화합물 및 이의 용도 |
| WO2016082934A1 (en) | 2014-11-26 | 2016-06-02 | Helmholtz-Zentrum für Infektionsforschung GmbH | Novel cystobactamides |
-
2014
- 2014-07-14 EP EP14747296.3A patent/EP3019615B1/en active Active
- 2014-07-14 US US14/904,654 patent/US20160145304A1/en not_active Abandoned
- 2014-07-14 AU AU2014289663A patent/AU2014289663B2/en active Active
- 2014-07-14 CN CN201480050439.3A patent/CN105793424B/zh active Active
- 2014-07-14 JP JP2016524705A patent/JP6730183B2/ja active Active
- 2014-07-14 CA CA2917767A patent/CA2917767C/en active Active
- 2014-07-14 WO PCT/EP2014/001925 patent/WO2015003816A2/en not_active Ceased
-
2018
- 2018-07-23 US US16/042,753 patent/US10793600B2/en active Active
-
2020
- 2020-06-10 US US16/897,497 patent/US11225503B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527215A5 (OSRAM) | ||
| US10590093B2 (en) | 1,2,4-oxadiazole derivatives as immunomodulators | |
| JP2019514426A5 (OSRAM) | ||
| JP2019512478A5 (OSRAM) | ||
| JP2017511321A5 (OSRAM) | ||
| JP2010527913A5 (OSRAM) | ||
| RU2014145819A (ru) | Бициклическое соединение | |
| MX2012011405A (es) | Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas. | |
| CA2910756A1 (en) | Compounds and methods of treating infections | |
| JP2013511553A5 (OSRAM) | ||
| EA201490709A1 (ru) | Адъювантное соединение | |
| RU2013140169A (ru) | Противоопухолевое терапевтическое средство | |
| JP2017523152A5 (OSRAM) | ||
| JP2020500916A5 (OSRAM) | ||
| WO2015192233A4 (en) | Compositions and methods for making (s)-norcoclaurine and (s)-norlaudanosoline, and synthesis intermediates thereof | |
| WO2010007316A3 (fr) | NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
| WO2022271810A2 (en) | Bicyclic peptidyl pan-ras inhibitors | |
| JP2013542980A5 (OSRAM) | ||
| MY198008A (en) | Crystal of benzofuran derivative free base and preparation method | |
| JP2020514299A5 (OSRAM) | ||
| JP2017519796A5 (OSRAM) | ||
| US6992081B2 (en) | Compounds to treat Alzheimer's disease | |
| MX2009007261A (es) | Vacuna de peptido foxp3. | |
| JP2012513982A5 (OSRAM) | ||
| KR102856089B1 (ko) | Tlr8 아고니스트 |